Press release

DIASORIN S.P.A. – THE BOARD OF DIRECTORS APPROVES THE RESULTS FOR THE FIRST QUARTER OF 2007: REVENUES AND PROFITABILITY CONTINUE TO IMPROVE

- Consolidated net revenues rise to 49.9 million euros, up from 46.1 million euros in the first quarter of 2006 (+8.3%);
- EBITDA[1] grow to 15.4 million euros (16.8 million euros net of nonrecurring charges), compared with 15.1 million euros in the first three months of 2006 (+10.8%*);
- Operating result (EBIT) increase to 11.9 million euros (13.3 million euros net of nonrecurring charges), as against 11.7 million euros in the opening quarter of 2006 (+14.1%*);
- Consolidated net result totals 6.8 million euros, up from 6.7 million euros in the first quarter of 2006;
- At March 30, 2007, net borrowings amounted to 30.9 million euros, down from 34.7 million euros at December 31, 2006.

Saluggia, May 16, 2007 – The Board of Directors of DiaSorin S.p.A., a company that operates in the global market for in vitro diagnostics with special emphasis on the immunodiagnostics segment, met under the chairmanship of Gustavo Denegri, Chairman of the Board of Directors. It approved the report on operations in the first quarter of 2007 submitted by Carlo Rosa, the Company's Chief Executive Officer.

Consolidated Operating and Financial Highlights

[1] The Company's Directors define EBITDA as the "result from operations" before amortization of intangibles and depreciation of property, plant and equipment. EBITDA, which the Company uses to monitor and assess the Group's operating performance, are not recognized as an accounting tool in the IFRS and, consequently, should not be viewed as an alternative gauge to assess the Group's operating performance. Because the composition of the EBITDA is not governed by the reference accounting principles, the computation criterion used by the Group could be different from the criterion used by other operators and/or groups and, consequently, may not be comparable.

*Net of nonrecurring charges.

In the first quarter of 2007, the Group reported higher revenues and a further improvement in profitability compared with the same period last year. DiaSorin's performance, while in line with expectations, was significantly affected by the appreciation of the euro versus the other main currencies used by the Group and large, nonrecurring costs incurred in connection with the preparations made by the Group's Parent Company to list its shares on the STAR segment of the Italian online stock market in Milan.

Consolidated **net revenues** were up 8.3% compared with the first three months of 2006, rising from 46.1 million euros to 49.9 million euros. This gain was made possible by a steady enlargement of the installed base of Liaison systems and a resulting increase in sales of reagents, which more than offset the negative impact of the appreciation of the euro versus the U.S. dollar and the Brazilian real. Restated on a comparable currency translation basis, revenues show an increase of 11.0%.

Breakdown of Revenues by Geographic Region

Revenues were up significantly in virtually all of the countries in which DiaSorin is present with its products, confirming the wisdom of the strategy of geographic expansion pursued by the Group.

In the markets in which DiaSorin operates directly, the Group continued to consolidate its competitive position. This was true not only in such key European countries as Spain (+14.1%), Belgium (+12.0%) and Germany (+11.3%), but also in less mature European markets, with decisively above-average growth rates.

Stated in euros, sales in the American market were about the same as in the first quarter of 2006. In real terms, they grew by 8.9%.

In the countries in which DiaSorin operates through a network of independent distributors, revenues were up 10.4%; thanks primarily to a strong results achieved in China with the support of DiaSorin Limited China, a joint venture established with the local partner, Fuyan International Management & Consulting Co. Ltd, and to new agreements signed at the end of 2006 for the distribution of Liaison-based products in Australia, New Zealand and Southeast Asia.

(in millions of euros)	2005	2006	% change
Europe	27.9	30.2	8.4%
North America (United States and Canada)	10.3	10.3	-
Rest of the world	7.8	9.3	19.0%
Total	46.1	49.9	8.3%

Breakdown of Revenues by Technology

A breakdown of revenues by technology confirms that the positive trend of recent years is continuing. Specifically, thanks to a steady enlargement of the installed base of systems and the expansion of the assay menu, sales of reagent kits for the Liaison system, which uses the latest-generation technology known as CLIA (ChemiLuminescent Immuno Assay), enjoyed a faster and accelerating growth rate than kits based on older technologies.

As a result, sales of products based on the CLIA technology accounted for a greater percentage (47.8%) of total revenues than in the first three months of 2006 (40.5%).

% of revenues contributed	First quarter 2006	First quarter 2007
RIA	15.2%	12.4%
ELISA	33.7%	30.0%
CLIA (Liaison)	40.5%	47.8%
Equipment and other revenues	10.6%	9.8%
Total	100.0	100.0%

The Group's operating result (**EBIT**) grew from 11.7 million euros in the first quarter of 2006 to 11.9 million euros in the same period this year. In the same period, **EBITDA** increased from 15.1 million euros in 2006 to 15.4 million euros in 2007. The Group's profitability benefited from an improvement in the cost of sales and a more favorable product mix in which more profitable products, such as those based on the CLIA technology, account for a rising share of total sales. At the same time, it was penalized by nonrecurring operating costs totaling 1.4 million euros incurred in connection with preparations for stock market listing. Restated net of these charges, EBIT and EBITDA show increases of 14.0% and 10.8%, respectively, and are equal to 26.7% and 33.7% of revenues, respectively.

The first quarter of 2007 ended with a consolidated **net result** of 6.8 million euros, equal to 13.6% of revenues.

At March 30, 2007, consolidated **net borrowings** amounted to 30.9 million euros, down from the 34.7 million euros owed at the end of 2006. The increase in liquid assets (12.0 million euros compared with 8.7 at December 31, 2006) accounts for this improvement.

Carlo Rosa, DiaSorin's Chief Executive Officer, noted that: "The data for the first quarter provide further confirmation of the success of our strategy, which is based, on the one hand, on expanding our geographic presence and entering promising new markets, such as China and Mexico, and, on the other, on enlarging our base of installed systems. By growing our installed based of LIAISON equipment, we are able to increase sales of the more profitable reagent lines."

* * *

About DiaSorin

DiaSorin S.p.A., an international player in the market for in vitro diagnostics, develops, produces and markets reagent kits for clinical laboratory diagnostics. The DiaSorin Group comprises 12 companies based in Europe, the United States, and Central and South America. It has more than 800 employees, including 70 research and development specialists, and operates three manufacturing and research facilities in Saluggia (Italy), Dietzenbach (Germany) and Stillwater (USA). Thanks to its direct sales organization and an international network of over 80 independent distributors, the Group is present in more than 60 countries, offering a broad array of high quality products that includes comprehensive lines for each of the clinical segments in which the Group operates: infectious and viral diseases, thyroid dysfunctions, oncology, fertility testing, etc.

Contacts:

Laura Villa
DiaSorin S.p.A.
Investor Relations Officer
laura.villa@diasorin.it
+39 0161487532
+39 348 15 11 542

Pasquo Cicchini
Hill & Knowlton
pcicchini@hillandknowlton.com
+39 02 31914245
+39 335 6417880

INCOME STATEMENT

	1Q07	1Q06
Net revenues	49.9	46.1
Gross profit	**31.9**	**28.2**
Sales and marketing expenses	(10.4)	(9.7)
Research and development costs	(2.5)	(2.1)
General and administrative expenses	(5.4)	(4.5)
Other operating income (expenses)	(1.7)	(0.2)
Operating result (EBIT)	**11.9**	**11.7**
Net financial expense	(0.8)	(0.9)
Result before tax	**11.1**	**10.8**
Income tax	(4.4)	(4.1)
Net result	**6.8**	**6.7**
EBITDA *	**15.4**	**15.1**

* The Company's Directors define EBITDA as the "result from operations" before amortization of intangibles and depreciation of property, plant and equipment. EBITDA, which the Company uses to monitor and assess the Group's operating performance, are not recognized as an accounting tool in the IFRS and, consequently, should not be viewed as an alternative gauge to assess the Group's operating performance. Because the composition of the EBITDA is not governed by the reference accounting principles, the computation criterion used by the Group could be different from the criterion used by other operators and/or groups and, consequently, may not be comparable.

BALANCE SHEET

(in millions of euros)	3/30/07	12/31/06
ASSETS		
Property, plant and equipment and goodwill	83.3	83.6
Other intangibles	15.5	14.8
Equity investments	0.1	0.1
Deferred-tax assets	8.1	8.4
Other non-current assets	0.3	0.2
Total non-current assets	**107.3**	107.0
Inventories	31.9	30.9
Trade receivables	50.1	44.7
Other current assets	3.8	2.8
Cash and cash equivalents	12.0	8.7
Total current assets	**97.8**	**87.0**
TOTAL ASSETS	**205.1**	**194.1**
LIABILITIES AND SHAREHOLDERS' EQUITY		
Share capital	50.0	50.0
Reserves	7.9	7.4
Retained earnings (Accumulated deficit)	29.8	8.1
Net result for the year	6.8	22.3
TOTAL SHAREHOLDERS' EQUITY	**94.5**	**87.7**
Total non-current liabilities	**56.3**	**56.2**
Trade payables	24.7	22.8
Other current liabilities	11.9	12.5
Income taxes payable	7.9	4.6
Current portion of long-term debt	9.8	9.9
Total current liabilities	**54.3**	**49.9**
TOTAL LIABILITIES	**110.7**	**106.3**
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	**205.1**	**194.1**

CASH FLOW STATEMENT

(in millions of euros)	1Q07	1Q06
Net cash from operating activities	7.5	9.3
Cash used for investing activities	(3.9)	(4.0)
Cash used for financing activities	(0.3)	(0.5)
Net change in cash and cash equivalents	**3.3**	**(4.8)**
Cash and cash equivalents at January 1	8.7	6.1
CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD	**12.0**	**10.9**